Amneal Pharmaceuticals, Inc.
NASDAQAMRX heads into its August 7 earnings release with analyst conviction building and options traders hedging more than usual. The analyst angle is the clearest setup. UBS raised its price target on AMRX for the second time in three weeks — from $23 to $25 on August 3 — while maintaining a Buy rating, placing its target roughly a third above the current price of $18.85. That follows a…
AMRX put-call ratio spikes to 0.49, highest since mid-June, as options traders turn defensive ahead of earnings today.
Snapshot as of 20 Aug 2026
AMRX heads into its August 7 earnings release with analyst conviction building and options traders hedging more than usual. The analyst angle is the clearest setup. UBS raised its price target on AMRX for the second…
Amneal Pharmaceuticals enters the week with a fresh analyst upgrade pulling against a softening price, just fifteen days before its next earnings print. The most notable development is on the Street. UBS raised its…
Amneal Pharmaceuticals heads into its August 7 earnings date with options positioning at its most bullish in months, even as the stock quietly built a 24% gain over the past month. The clearest signal this week is in…
AMRX enters this week's session caught between a fresh analyst upgrade and a stock that has shed 15% in a month — a gap that defines the current setup for Amneal Pharmaceuticals. Options positioning is the most charged…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for AMRX — free to start on ORTEX.
Sign up for free →Open AMRX on ORTEX